Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

24.1%

7 terminated/withdrawn out of 29 trials

Success Rate

70.8%

-15.7% vs industry average

Late-Stage Pipeline

41%

12 trials in Phase 3/4

Results Transparency

71%

12 of 17 completed trials have results

Key Signals

3 recruiting12 with results6 terminated

Enrollment Performance

Analytics

Phase 2
11(39.3%)
Phase 3
10(35.7%)
Phase 1
5(17.9%)
Phase 4
2(7.1%)
28Total
Phase 2(11)
Phase 3(10)
Phase 1(5)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT02682407Phase 2Terminated

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Role: lead

NCT04247906Unknown

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Role: lead

NCT03205995Phase 3Terminated

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Role: lead

NCT03608033Phase 3Terminated

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Role: lead

NCT05972967Phase 2Completed

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Role: lead

NCT06209736Phase 2Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Role: lead

NCT05855083Phase 2Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Role: lead

NCT02222545Phase 2Completed

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Role: lead

NCT06298955Phase 2Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Role: lead

NCT03864133Phase 4Completed

No Drop Post-Op Cataract Surgery

Role: collaborator

NCT05889299Phase 1Unknown

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Role: lead

NCT04829799Phase 4Withdrawn

Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain

Role: collaborator

NCT02132312Phase 3Completed

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

Role: lead

NCT01406561Phase 3Completed

Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

Role: lead

NCT02074410Phase 2Terminated

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Role: lead

NCT01952132Phase 2Completed

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

Role: lead

NCT02093689Phase 3Terminated

Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery

Role: lead

NCT01395797Phase 1Terminated

Pioglitazone for Heroin and for Nicotine Dependence

Role: collaborator

NCT01579565Phase 3Completed

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Role: lead

NCT01395784Phase 2Completed

Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone

Role: collaborator